Pendar develops real-time measurement systems for oxygen delivery and consumption, utilizing a wavelength-tunable Quantum Cascade Laser array to provide insights into tissue health and mitochondrial function. Their technology addresses the need for precise monitoring of oxygen dynamics in clinical and research settings, enhancing understanding of tissue oxygenation.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing tissue health and mitochondrial function often lack the real-time precision needed to understand oxygen delivery and consumption dynamics. Existing technologies may not provide sufficient insight into the path of oxygen from the bloodstream to the tissues and ultimately into the mitochondria.
Solution
Pendar is developing real-time measurement systems that utilize a wavelength-tunable Quantum Cascade Laser (QCL) array to provide detailed insights into tissue oxygenation and mitochondrial redox state. Their technology aims to illuminate the path of oxygen from the bloodstream, into tissues, and ultimately inside of the mitochondria. By offering a local measurement of mitochondrial redox state, Pendar's tools may provide new insights into tissue health and the adequacy of oxygen delivery. The QCL technology, exclusively licensed by Pendar, enables next-generation technologies for researchers and clinicians.
Target Audience
The primary target audience includes researchers and clinicians seeking advanced tools for real-time monitoring of tissue oxygenation and mitochondrial function.
Features
- Wavelength-tunable Quantum Cascade Laser (QCL) array for precise spectral analysis.
- Real-time measurement of oxygen delivery and consumption.
- Monitoring of mitochondrial redox state to assess tissue health.